You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》默沙東(MRK.US)季度多賺46%勝預期 新冠藥銷售為市場預期5倍
阿思達克 10-27 08:23
道指成分股,美國藥廠默沙東(MRK.US)公布第三季業績。季度純利按年升46%至47.45億美元,每股季度攤薄純利1.86美元,經調整後為2.13美元,高於市場預期的1.95美元,季度銷售按年升7%至159.62億美元,市場預期為153億美元。 其中新冠治療藥Lagevrio季度銷售升47%至6.4億美元,遠超市場預期的1.2億美元。腸癌藥Keytruda季度銷售63.4億美元,高於市場預期的62.2億美元;子宮頸癌疫苗Gardasil季度銷售25.9億美元,低於市場預期的26.9億美元。 公司上調全年銷售預測,由介乎586億至596億美元,上調至介乎597億至602億美元。公司亦上調對Lageviro全年銷售預測至13億美元。 默沙東股價昨日(26日)升1.9%報105.55美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account